Walgreens Boots Alliance — Q1 2021 Earnings Presentation
33 slides from Walgreens Boots Alliance's earnings presentation, Jan 7, 2021
Slide 1: Fiscal 2021 First Quarter Results
Fiscal 2021 First Quarter Results January 7, 2021
Slide 2: Safe harbor and non-GAAP
Safe harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that are not historical including, without limitation, estimates of and goals for future financial, tax
Slide 3: Overview
Overview • Strong start to the fiscal year • Current operating environment demonstrates the importance of being a pharmacy-led healthcare provider • Confident in full year adj. EPS target although situation remains fluid • Executed strategic transactions: − divestiture of Alliance Healthcare − accel
Slide 4: 1Q financial highlights
1Q financial highlights • 1Q adjusted EPS $1.22, exceeding expectations − -11.6% below prior year in constant currency − estimated COVID-19 impact $0.26 to $0.30 − good performance underpinned by constant currency sales growth +5.2% and stronger results from Boots UK and Opticians • Strong cash gene
Slide 5: 1Q financial highlights
1Q financial highlights Reported currency Constant currency 1Q21 Δ vs. 1Q20 Δ vs. 1Q20 $ in millions (except EPS and % change) Sales $36,307 + 5.7% + 5.2% Operating income: GAAP - $440 - 143.5% Adjusted $1,318 - 9.9% - 10.1% Net earnings: GAAP - $308 - 136.4% Adjusted $1,052 - 13.9% - 14.3% EPS: GAA
Slide 6: Retail Pharmacy USA – financials
Retail Pharmacy USA – financials $ in millions (except %) 1Q21 Δ vs. 1Q20 Sales $27,163 + 3.9% Adj. gross profit $5,649 - 1.8% Adj. SG&A % of sales 17.2% - 0.4%p Adj. operating margin 3.6% - 0.8%p Adj. operating income $989 - 14.4% © 2021 Walgreens Boots Alliance, Inc. All rights reserved. Refer to
Slide 7: Retail Pharmacy USA – pharmacy
Retail Pharmacy USA – pharmacy 1Q 1Q 1Q21 vs. 1Q20 Total Comparable Pharmacy sales + 5.9% + 5.0% Prescriptions + 1.1% + 2.7% • 1Q comp scripts up +2.7%; held back by adverse COVID-19 impacts -210bps – significantly weaker cough cold flu season negatively impacting comp scripts partly offset by highe
Slide 8: Retail Pharmacy USA – retail
Retail Pharmacy USA – retail 1Q21 vs. 1Q20 1Q Total retail sales - 2.2% Comp. retail sales + 0.4% • 1Q comp retail sales grew +0.4%, as COVID-19 weighed on results; ex tobacco and e-cigarettes, up +1.9% ‒ Health & Wellness grew +4.1%, +11.6% excluding cough cold flu impact; seasonal flu categories n
Slide 9: Retail Pharmacy International – financials
Retail Pharmacy International – financials Constant currency $ in millions (except %) 1Q21 Δ vs. 1Q20 Sales $2,574 - 8.2% Adj. operating margin 3.3% + 0.3%p Adj. operating income $84 + 0.6% • Adj. operating income, broadly in line with prior year, despite a significant adverse year over year COVID-1
Slide 10: Boots UK – financials
Boots UK – financials 1Q 1Q 1Q21 vs. 1Q20 (Constant currency) Total Comparable Pharmacy sales - 3.7% + 2.5% Retail sales - 15.9% - 9.1% • Comp pharmacy sales impacted by lower demand for scripts & Rx services, notably in city centers, offset by NHS funding phasing • Comp retail sales -9.1%; sequenti
Slide 11: Retail Pharmacy International – initiatives
Retail Pharmacy International – initiatives Boots UK turnaround key priority for FY21 • Strength in Boots brand enabling quick turnaround • Boots.com: a top UK online destination for consumers − strong growth, 1Q sales doubled vs. prior year − biggest ever seasonal sales period, November orders almo
Slide 12: Pharmaceutical Wholesale – financials
Pharmaceutical Wholesale – financials Constant currency $ in millions (except %) 1Q21 Δ vs. 1Q20 Sales $7,125 + 16.3% Adj. operating margin 1.9% - 0.3%p Adj. operating income $244 + 7.4% • Sales led by emerging markets, PPE contracts in France, and an 8 percentage point contribution from consolidati
Slide 13: Cash flow
Cash flow Better/(worse) $ in millions 1Q21 Δ vs. 1Q20 Operating cash flow $1,195 $134 Cash capital expenditure $431 ($44) Free cash flow $763 $90 • YTD free cash flow grew +13% versus prior year • Key initiatives include Rx inventory optimization and improved payable terms • Free cash flow benefite
Slide 14: Transformational Cost Management Program
Transformational Cost Management Program On target to deliver in excess of $2.0 billion in annual cost savings by FY22 • Store optimization: executed U.S. 232 of 250 planned, Boots UK 158 of 200 planned • Boots UK restructuring plan now targeting 11% reduction in workforce (vs. 7% previously) • Adva
Slide 15: Fiscal year 2021 guidance
Fiscal year 2021 guidance Constant Currency adjusted EPS growth: low-single digit • Company reiterates full year guidance with profile skewed to opportunity • First half EPS anticipated to be broadly in-line with expectations set in October 2020 − 1Q results exceeded expectations and guidance − 2Q a
Slide 16: Portfolio Transformation: Alliance Healthcare Divestiture
Portfolio Transformation: Alliance Healthcare Divestiture • Divestiture unlocks significant value for WBA • Multi-faceted transaction with AmerisourceBergen − sale of majority of existing wholesale business − extension of existing U.S. Distribution agreement for 3 years until 2029 − collaboration to
Slide 17: Divestiture of Alliance Healthcare: Overview
Divestiture of Alliance Healthcare: Overview • Unlocks significant value with gross proceeds of ~$6.5bn* − gross proceeds of $6.275bn in cash plus 2.0 million shares in AmerisourceBergen − after tax cash proceeds of ~$6.0bn − expected after-tax gain of ~$1.0bn • Ownership in AmerisourceBergen increa
Slide 18: Retail Pharmacy USA – initiatives
Retail Pharmacy USA – initiatives Providing essential services while accelerating our transformation • Modernizing pharmacy operating model: improve efficiency, provide better service & free up pharmacist time • Administering COVID-19 vaccines in phase 1 to high risk groups & medical care providers
Slide 19: Refer to safe harbor and non-GAAP on page 2 and endnotes on page 20
© 2021 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on page 2 and endnotes on page 20 19
Slide 20: Endnotes
Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures ◦ The company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating
Slide 21: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation to the most directly comparable financial measures calculated and presented in accordance with generally accepted accou
Slide 22: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS (LOSS) Three months ended November 30, Change vs. FY20 2020 2019 Amount Percent Net earnings (loss) attributable to Walgreens Boots Alliance,
Slide 23: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended November 30, Change vs. FY20 2020 2019 Amount Percent 10 Diluted net earnings (loss) per common share (GAAP) $ (
Slide 24: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBergen consisten
Slide 25: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended November 30, 2020 Retail Pharmacy Pharmaceutical Walgreens Boots Retail Pharmacy USA International Wholesale1 Eliminations Alliance, Inc
Slide 26: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended November 30, 2019 Retail Pharmacy Pharmaceutical Walgreens Boots Retail Pharmacy USA International Wholesale1 Eliminations Alliance, Inc
Slide 27: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS (LOSS) IN AMERISOURCEBERGEN Three months ended November 30, 2020 2019 Equity earnings (loss) in AmerisourceBergen (GAAP) $ (1,373) $ 13 Lit
Slide 28: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended November 30, 2020 Three months ended November 30, 2019 Earnings (loss) Earnings before before income tax Income tax Effective tax income
Slide 29: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended November 30, 2020 2019 Net cash provided by operating activities (GAAP) $ 1,195 $ 1,061 Less: Additions to property, plan
Slide 30: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) WHOLESALE AND RETAIL BUSINESSES DIVESTED - ADJUSTED OPERATING INCOME Twelve months ended August 31, 2020 Operating income (GAAP) $ 319 Acquisition-related
Slide 31: Comparable sales methodology change
Comparable sales methodology change 1 Walgreens Boots Alliance, Inc. and Subsidiaries Restatement of Comparable Sales (unaudited) Percent increase (decrease) Three months ended November 30, 2019 Three months ended February 29, 2020 Three months ended May 31, 2020 Three months ended August 31, 2020 T
Slide 32: Comparable sales methodology change
Comparable sales methodology change 1 Walgreens Boots Alliance, Inc. and Subsidiaries Restatement of Comparable Sales (unaudited) Percent increase (decrease) Three months ended November 30, 2018 Three months ended February 28, 2019 Three months ended May 31, 2019 Three months ended August 31, 2019 T
Slide 33: Currency sensitivity
Currency sensitivity Exchange Rates/Impact FY20 Sep '20 Sensitivity Dec '20 Sensitivity GBP/USD 1.27 1.29 1.32 EUR/USD 1.11 1.15 1.18 TRY/USD 0.16 0.14 0.12 Fx Sales Impact vs. FY20 ~$275m/~0.2 ~$970m/~0.7% Fx Adj. Operating Income Impact vs. FY20 ~$0m/~0.0% ~$15m/~0.3% Fx Adj. EPS Impact vs. FY20 ~
Walgreens Boots Alliance — Q1 2021 Earnings Presentation on 6ix